

Edgar Filing: CHIRON CORP - Form SC 13D/A

CHIRON CORP
Form SC 13D/A
April 03, 2006

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 14)*

CHIRON CORPORATION

(Name of Issuer)

COMMON STOCK, PAR VALUE \$0.01 PER SHARE

(Title of Class of Securities)

170040109

(CUSIP Number of Class of Securities)

WAYNE P. MERKELSON
NOVARTIS CORPORATION
608 FIFTH AVENUE
NEW YORK, NEW YORK 10020
(212) 307-1122

ANDREW R. BROWNSTEIN, ESQ.
TREVOR S. NORWITZ, ESQ.
WACHTELL, LIPTON, ROSEN & Katz
51 WEST 52 STREET
NEW YORK, NEW YORK 10019
(212) 403-1000

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications on Behalf of Filing Persons)

APRIL 3, 2006

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. |_|

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

Edgar Filing: CHIRON CORP - Form SC 13D/A

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

2

CUSIP No. 170040109

1. NAMES OF REPORTING PERSONS:
Novartis Biotech Partnership, Inc.

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):
06-1415318

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

(A) -

(B) -

3. SEC USE ONLY:

4. SOURCE OF FUNDS (SEE INSTRUCTIONS):
AF

5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

-

6. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

Number of Shares Beneficially Owned by Each Reporting Person With

7. SOLE VOTING POWER
0

8. SHARED VOTING POWER
130,845,765

Edgar Filing: CHIRON CORP - Form SC 13D/A

3

9. SOLE DISPOSITIVE POWER
0

10. SHARED DISPOSITIVE POWER
130,845,765

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
130,845,765

12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
52.8%

14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO

4

CUSIP No. 170040109

1. NAMES OF REPORTING PERSONS:
Novartis Corporation

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):
13-1834433

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

(A)

(B)

3. SEC USE ONLY:

Edgar Filing: CHIRON CORP - Form SC 13D/A

4. SOURCE OF FUNDS (SEE INSTRUCTIONS):

AF

5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(D) OR 2(E)

6. CITIZENSHIP OR PLACE OF ORGANIZATION

New York

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7. SOLE VOTING POWER

0

8. SHARED VOTING POWER

130,853,221

5

9. SOLE DISPOSITIVE POWER

0

10. SHARED DISPOSITIVE POWER

130,853,221

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

130,853,221

12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE
INSTRUCTIONS)

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

52.8%

14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

6

Edgar Filing: CHIRON CORP - Form SC 13D/A

CUSIP No. 170040109

1. NAMES OF REPORTING PERSONS:
Novartis Pharma AG

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

(A)

(B)

3. SEC USE ONLY:

4. SOURCE OF FUNDS (SEE INSTRUCTIONS):
WC

5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(D) OR 2(E)

6. CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7. SOLE VOTING POWER
0

8. SHARED VOTING POWER
5,469,770

7

9. SOLE DISPOSITIVE POWER
0

10. SHARED DISPOSITIVE POWER
5,469,770

Edgar Filing: CHIRON CORP - Form SC 13D/A

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,469,770

12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.2%

14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO

8

CUSIP No. 170040109

1. NAMES OF REPORTING PERSONS:
Novartis AG

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

(A)

(B)

3. SEC USE ONLY:

4. SOURCE OF FUNDS (SEE INSTRUCTIONS):
WC

5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

6. CITIZENSHIP OR PLACE OF ORGANIZATION
Switzerland

Edgar Filing: CHIRON CORP - Form SC 13D/A

Number of Shares Beneficially Owned by Each Reporting Person With 7. SOLE VOTING POWER
0

8. SHARED VOTING POWER
136,322,991

9

9. SOLE DISPOSITIVE POWER
0

10. SHARED DISPOSITIVE POWER
136,322,991

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
136,322,991

12. CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) | |

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
55%

14. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO

10

ITEM 1. SECURITY AND ISSUER

This Amendment No. 14 to Schedule 13D relates to Common Stock, par value \$0.01 per share (the "Common Stock"), of Chiron Corporation, a Delaware corporation (the "Company"). Novartis AG ("Novartis"), Novartis Corporation, ("Novartis Corp"), Novartis Biotech Partnership, Inc. ("Biotech"), and Novartis Pharma AG ("Novartis Pharma" and, together with Novartis, Novartis Corp and Biotech the "Reporting Persons") hereby amend the Schedule 13D.

ITEM 4. PURPOSE OF TRANSACTION

Item 4 is hereby amended and supplemented by adding the following:

On April 3, 2006, the Company, Novartis Corp and Biotech entered into

Edgar Filing: CHIRON CORP - Form SC 13D/A

Amendment No. 1 (the "Amendment") to the Agreement and Plan of Merger, dated as of October 30, 2005, by and among the Company, Novartis Corp, Novartis Biotech, and for purposes of Section 10.14 thereof only, Novartis AG (the "Merger Agreement"). The Amendment amends the Merger Agreement by (1) increasing the amount of the consideration to be paid to holders of shares of the Company's common stock, par value \$0.01 per share ("Common Stock") upon consummation of the merger contemplated thereby (the "Merger") from \$45.00 per share of Common Stock to \$48.00 per share of Common Stock (such increased amount, the "Merger Consideration"), and (2) providing that the only vote of holders of Common Stock required to approve the Merger is the affirmative vote of a majority of the outstanding shares of Common Stock, which is the vote required by Delaware law. In addition, the Amendment provides that shares of Common Stock owned by any non-U.S. affiliate of Parent will not be cancelled in the Merger, but instead will be converted into the right to receive the Merger Consideration.

Also on April 3, 2006, Novartis Corp, Chiron and CAM North America LLC ("CAM") entered into a letter agreement (the "Letter Agreement") that provides that, subject to applicable fiduciary and/or regulatory obligations, CAM will vote or cause to be voted all shares of Common Stock over which CAM or certain related entities have voting authority or control in favor of the proposal to adopt the Merger Agreement at the special meeting of Chiron's stockholders. CAM also agreed to file an amendment to its Schedule 13D to such effect.

Novartis issued a press release on April 3, 2006 announcing the execution of the Amendment and the Letter Agreement. The Amendment, the Letter Agreement and the press release are filed as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 hereto, respectively, and are incorporated herein by reference.

ITEM 5. INTEREST IN SECURITIES OF ISSUER

Items 5(a) and 5(b) are hereby amended in their entirety as follows:

(a) and (b) As of the date of this Amendment, Biotech is the record holder of 80,739,404 shares of Common Stock. In addition, pursuant to the Market Price Option Agreement, Biotech or its designee, which must be Novartis or a subsidiary thereof, has the right to purchase from the Company under certain circumstances such number of shares of Common Stock as are necessary for the Reporting Persons to maintain collectively up to a 55% ownership interest in the Company, which as of April 3, 2006, constituted the right to purchase an additional 50,106,361 shares, based on 197,753,623 shares of Common Stock outstanding at March 3, 2006, as reported in the Company's Proxy Statement for a special meeting of Company stockholders to be held on April 12, 2006, first mailed to Company stockholders on or about March 6, 2006 and filed with the Securities and Exchange Commission on Schedule 14A on March 6, 2006. Biotech is the beneficial owner of 130,845,765 shares of Common Stock, or 52.8% of the Common Stock, assuming Biotech exercises its right to purchase the additional shares of Common Stock pursuant to Market Price Option Agreement. Biotech has shared power to vote or to direct the vote and shared power to dispose or to direct the disposition with respect to all the shares of Common Stock beneficially owned by it.

Novartis Corp is the record holder of 7,456 shares of Common Stock. After adjusting the total number of shares beneficially owned by Novartis Corp to include the 130,845,765 shares beneficially owned by Biotech, Novartis Corp is the beneficial owner of 130,853,221 shares of Common Stock or 52.8% of the Common Stock, assuming Biotech exercises its right to purchase the additional shares of Common Stock pursuant to Market Price Option Agreement. Novartis Corp has shared power to vote or to direct the vote and shared power to dispose or to direct the disposition with respect to all the shares of Common Stock beneficially owned by it.

Novartis Pharma is the record holder of 5,469,770 shares of Common Stock, or 2.2% of the Common Stock, assuming Biotech exercises its right to purchase the additional shares of Common Stock pursuant to Market Price Option Agreement. Novartis Pharma has shared power to vote or to direct the vote and shared power to dispose or to direct the disposition with respect to all the shares of Common Stock beneficially owned by it.

Novartis is the beneficial owner of the shares of Common Stock beneficially owned by Novartis Pharma, Novartis Corp and Biotech. Novartis beneficially owns 136,322,991 shares of Common Stock, giving it a 55% beneficial interest in the Company, assuming Biotech exercises its right to purchase the additional shares of Common Stock pursuant to Market Price Option Agreement. Novartis has shared power to vote or to direct the vote and shared power to dispose or to direct the disposition of the shares of Common Stock beneficially owned by Biotech, Novartis Corp and Novartis Pharma.

To the best knowledge of each of the Reporting Persons, none of the persons listed on Schedule I hereto with respect to such Reporting Person is the beneficial owner of any shares of Common Stock, other than Raymund Breu, who is the beneficial owner of 65,216 shares of Common Stock.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

- 99.1 Amendment No. 1, dated as of April 3, 2006, to the Agreement and Plan of Merger, dated as October 30, 2005, by and among Novartis Corporation, Novartis Biotech Partnership, Inc., Chiron Corporation and, for purposes of Section 10.14 thereof only, Novartis AG.
- 99.2 Press Release, dated as of April 3, 2006
- 99.3 Letter Agreement, dated as of April 3, 2006, by and among Novartis Corporation, CAM North America LLC and Chiron Corporation.
- 99.4 Joint Filing Agreement, by and among Novartis Biotech Partnership, Inc., Novartis Corporation, Novartis Pharma AG and Novartis AG, dated as of April 3, 2006.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 3, 2006

NOVARTIS BIOTECH
PARTNERSHIP, INC.

By: /s/ Wayne P. Merkelson

Name: Wayne P. Merkelson
Title: Vice President

Edgar Filing: CHIRON CORP - Form SC 13D/A

NOVARTIS CORPORATION

By: /s/ George Miller

Name: George Miller
Title: General Counsel

NOVARTIS PHARMA AG

By: /s/ Thomas Werlen

Name: Thomas Werlen
Title: Group General Counsel

By: /s/ Urs Baerlocher

Name: Urs Baerlocher
Title: Head Legal and General
Affairs

NOVARTIS AG

By: /s/ Bruno Heynen

Name: Bruno Heynen
Title: Corporate Secretary

By: /s/ Urs Baerlocher

Name: Urs Baerlocher
Title: Head Legal and General
Affairs

Exhibit Index

EXHIBIT NUMBER	EXHIBIT NAME
99.1	Amendment No. 1, dated as of April 3, 2006, to the Agreement and Plan of Merger, dated as October 30, 2005, by and among Novartis Corporation, Novartis Biotech Partnership, Inc., Chiron Corporation and, for purposes of Section 10.14 thereof only, Novartis AG.
99.2	Press Release, dated as of April 3, 2006.
99.3	Letter Agreement, dated as of April 3, 2006, by and among Novartis Corporation, CAM North America LLC and Chiron Corporation.
99.4	Joint Filing Agreement, by and among Novartis Biotech

Edgar Filing: CHIRON CORP - Form SC 13D/A

Partnership, Inc., Novartis Corporation, Novartis Pharma AG
and Novartis AG, dated as of April 3, 2006.
